To explore the relationship between non-alcoholic fatty liver disease (NAFLD) and coronary artery disease (CAD), emphasizing the critical need to address metabolic risks beyond genetic factors for improved patient outcomes.
Key Findings:
NAFLD is associated with an increased risk of cardiovascular diseases, including CAD, highlighting the need for early intervention.
The new term metabolic dysfunction-associated steatotic liver disease (MASLD) broadens the definition of fatty liver disease, emphasizing metabolic risk factors.
No causal association was found between genetically predicted NAFLD and CAC, suggesting a need for further investigation.
Metabolic factors, rather than NAFLD itself, likely mediate the association with CAC, indicating a complex interplay.
Interpretation:
NAFLD should be viewed as a marker of advanced metabolic dysfunction, necessitating a comprehensive evaluation of cardiovascular risk factors, including lifestyle and metabolic health.
Limitations:
The study's findings may not apply to all patient subgroups, particularly those with advanced liver fibrosis, which could skew results.
Social determinants of health affecting patient outcomes were not fully addressed, potentially limiting the applicability of findings.
Conclusion:
A comprehensive, patient-centered approach that integrates metabolic health and social determinants is essential for improving outcomes in patients with NAFLD and CAD, ensuring equitable access to care.
